A new study released to coincide with World Cancer Research Day today argues that wider access to clinical trials of new ...
Dr. Chirag Jani, a Phoebe Cancer Center hematologist and oncologist beloved by his patients and well-respected by his peers, has been named president of the Georgia Society of Clinical Oncology. Jani ...
Highlights include new safety and efficacy data of Barrigel™ rectal spacer, the first and only sculptable rectal spacer1-3 • ...
Phase 3 ENLIGHTED study enrollment completion expected by first quarter of 2025TEL AVIV, Israel, Sept. 27, 2024 (GLOBE ...
UCLA Health Jonsson Comprehensive Cancer Center researchers and physicians who specialize in treating patients with radiation ...
Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated ...
Camrelizumab increased the 3-year event-free survival rate vs standard of care from 77.3% to 86.9%, translating to a 44% ...
Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the presentation of ...
MedPage Today on MSN3d
Cancer Diagnoses Slow to Recover From Effects of COVID PandemicThe researchers noted that multiple studies have documented substantial declines in cancer incidence across multiple types of ...
The FDA has approved osimertinib (Tagrisso) for locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) ...
Researchers at Fred Hutch Cancer Center identified a substantial increase over the past decade in the proportion of patients with cancer in the U.S. who participate in pharmaceutical industry ...
British drug major AstraZeneca PLC (AZN, AZN.L) announced Thursday that its Tagrisso (osimertinib) has been approved in the US for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback